Insulet Corp
Closed
SectorHealthcare
157.28 -2.62
Overview
Share price change
24h
Min
155.75
Max
161.46
Income | -11M 91M |
|---|---|
Sales | -22M 762M |
P/E Sector Avg | 37.329 60.549 |
EPS | 1.3 |
Profit margin | 11.96 |
Employees | 5,400 |
EBITDA | -23M 154M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +40.43% upside |
Next Earnings | 5 sie 2026 |
|---|
Market Cap | -805M 11B |
|---|---|
Previous open | 159.9 |
Previous close | 157.28 |
Insulet Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Insulet Corp Forecast
Price Target
By TipRanks
40.43% upside
12 Months Forecast
Average 226.86 USD 40.43%
High 294 USD
Low 172 USD
Based on 22 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.